NCT00095992 2023-08-04
SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer
Canadian Cancer Trials Group
Phase 2 Completed
Clinical Trials
9 trialsNCT00089973 2018-02-26
Study Of Ispinesib In Subjects With Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00095628 2017-03-06
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00103311 2015-03-02
SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00354250 2013-06-05
Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00095953 2013-05-17
SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00096499 2013-01-25
SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel
National Cancer Institute (NCI)
Phase 2 Completed
NCT00085813 2010-10-04
Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00097409 2010-10-04
Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer
GlaxoSmithKline
Phase 2 Completed